• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Accolade Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    4/8/25 9:57:38 AM ET
    $ACCD
    Business Services
    Consumer Discretionary
    Get the next $ACCD alert in real time by email
    false02-280001481646NASDAQ00014816462025-04-082025-04-08

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549


    FORM 8-K


    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 8, 2025



    Accolade, Inc.
    (Exact name of Registrant as Specified in Its Charter)



    Delaware
    001-39348
    01-0969591
    (State or Other Jurisdiction of Incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)

    1201 Third Avenue, Suite 1700
    Seattle, WA 98101
    (Address of Principal Executive Offices and Zip Code)
    (206) 926-8100
    (Registrant’s Telephone Number, Including Area Code)
    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)



    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
    Trading
    Symbol(s)
    Name of each exchange
    on which registered
    Class A common stock, par value $0.0001 per share
    ACCD
    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Introductory Note

    This Current Report on Form 8-K is being filed in connection with the completion of the previously announced Merger (as defined below) pursuant to the Agreement and Plan of Merger, dated as of January 8, 2025 (the “Merger Agreement”), by and among Accolade, Inc., a Delaware corporation (the “Company”), Transcarent, Inc., a Delaware corporation (“Parent”), and Acorn Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (“Merger Sub”).

    On April 8, 2025 (the “Closing Date”), pursuant to the Merger Agreement, Merger Sub merged with and into the Company (the “Merger”), with the Company surviving the Merger as an indirect wholly owned subsidiary of Parent.

    The foregoing description of the Merger Agreement and the transactions contemplated thereby contained in this Introductory Note, including the Merger, does not purport to be complete and is subject to and qualified in its entirety by reference to the Merger Agreement, a copy of which is filed as Exhibit 2.1 hereto and is incorporated by reference herein.

    Item 1.01
    Entry into a Material Definitive Agreement.

    The information set forth in the Introductory Note of this Current Report on Form 8-K is incorporated by reference into this Item 1.01.

    On the Closing Date, the Company and U.S. Bank Trust Company, National Association, a national banking association organized under the laws of the United States of America (as successor in interest to U.S. Bank National Association), as trustee (the “Trustee”), entered into the First Supplemental Indenture, dated as of the Closing Date (the “First Supplemental Indenture”), to the Indenture, dated as of March 24, 2021, by and between the Company and the Trustee (the “Original Indenture” and, together with the First Supplemental Indenture, the “Indenture”), relating to the Company’s 0.50% Convertible Senior Notes due 2026 (the “Notes”). As of the Closing Date, $211,041,000 aggregate principal amount of the Notes were outstanding.

    As a result of the Merger, and pursuant to the First Supplemental Indenture, at and after the effective time of the Merger (the “Effective Time”), the right to convert each $1,000 principal amount of Notes was changed into a right to convert such principal amount of Notes into an amount of cash equal to the Conversion Rate (as defined in the Indenture) in effect on the relevant Conversion Date (as defined in the Indenture) (subject to any adjustment pursuant to the Indenture, including any increase as a result of a Make-Whole Fundamental Change (as defined in the Indenture)) multiplied by $7.03 (which is an amount equal to the Merger Consideration (as defined below)).

    The consummation of the Merger constitutes a Merger Event, a Fundamental Change and a Make-Whole Fundamental Change (each as defined in the Indenture) under the Indenture. The effective date of the Merger Event, Fundamental Change and Make-Whole Fundamental Change in respect of the Notes is the Closing Date.

    As a result of the Fundamental Change, each holder of Notes will have the right to require the Company to repurchase its Notes pursuant to the terms and procedures set forth in the Indenture for a cash repurchase price equal to the Fundamental Change Repurchase Price (as defined in the Indenture) on May 6, 2025.

    The foregoing descriptions of the Indenture and the transactions contemplated thereby do not purport to be complete and are subject to and qualified in their entirety by reference to the full text of the Indenture. A copy of the Original Indenture was filed as Exhibit 4.3 to the Current Report on Form 10-K filed by the Company with the Securities and Exchange Commission (the “SEC”) on April 26, 2024. A copy of the First Supplemental Indenture is filed as Exhibit 4.1 hereto. The Indenture and the First Supplemental Indenture are incorporated by reference into this Item 1.01. This Current Report on Form 8-K does not constitute an offer to tender for, or purchase, or a solicitation of an offer to tender for, or purchase, any of the Notes or any other security.


    Item 2.01
    Completion of Acquisition or Disposition of Assets.

    The information set forth in the Introductory Note and under Items 3.01, 5.01, 5.02 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.

    Pursuant to the Merger Agreement, at the Effective Time, each share of common stock of the Company, par value $0.0001 per share (the “Company Common Stock”), that was issued and outstanding immediately prior to the Effective Time (each, a “Share”, and collectively, the “Shares”), subject to certain customary exceptions specified in the Merger Agreement, was automatically converted into the right to receive $7.03 in cash, without interest (the “Merger Consideration”) and subject to applicable withholding taxes.

    Pursuant to the Merger Agreement, at the Effective Time, (i) all Shares underlying Company stock options outstanding immediately prior to the Effective Time that were vested, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee, with an exercise price per Share that is less than the Merger Consideration (each, a “Vested Company Option”), (ii) restricted stock units outstanding immediately prior to the Effective Time that were vested, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee, (each, a “Vested Company RSU”) and (iii) restricted stock units outstanding immediately prior to the Effective Time that vested, or became eligible to vest, based on the achievement of performance conditions and that were vested or that became vested at the Effective Time, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee (each, a “Vested Company PSU”) were canceled and converted into the right to receive the Merger Consideration (or, in the case of such Vested Company Option, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable tax withholdings.

    Company stock options, whether vested or unvested, that had an exercise price per Share that was equal to or greater than the Merger Consideration were canceled without consideration.

    At the Effective Time, the portion of each Company stock option, restricted stock unit, including any restricted stock unit that vested, or became eligible to vest, based on the achievement of performance conditions that were not Vested Company Options, Vested Company RSUs, or Vested Company PSUs were canceled without consideration.

    The foregoing description of the Merger Agreement and the transactions contemplated thereby contained in this Item 2.01, including the Merger, does not purport to be complete and is subject to and qualified in its entirety by reference to the Merger Agreement, a copy of which is filed as Exhibit 2.1 hereto and is incorporated by reference herein.

    Item 3.01
    Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

    The information set forth in the Introductory Note and under Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.01.

    On April 8, 2025, the Company (i) notified The Nasdaq Stock Market LLC (“Nasdaq”) of the consummation of the Merger and (ii) requested that Nasdaq file a Form 25 Notification of Removal from Listing and/or Registration with the SEC to remove the Company Common Stock from listing on Nasdaq and deregister the Company Common Stock pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

    After effectiveness of the Form 25, the Company intends to file with the SEC a Certification and Notice of Termination on Form 15 to terminate the registration of the Company Common Stock under the Exchange Act and suspend the Company’s reporting obligations under Section 13 and Section 15(d) of the Exchange Act. Trading of the Company Common Stock on Nasdaq was halted prior to the opening of trading on the Closing Date.

    Item 3.03
    Material Modification to Rights of Security Holders.

    The information set forth in the Introductory Note and under Items 2.01, 3.01, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.

    Except as described in Item 2.01, pursuant to the Merger Agreement, each Share, subject to certain customary exceptions specified in the Merger Agreement, was automatically converted into the right to receive the Merger Consideration.


    Item 5.01
    Changes in Control of Registrant.

    The information set forth in the Introductory Note and under Items 2.01, 3.01, 3.03, 5.02 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01.

    As a result of the Merger, at the Effective Time, a change in control of the Company occurred, and the Company became an indirect wholly owned subsidiary of Parent.

    Item 5.02
    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    The information set forth in the Introductory Note and under Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.02.

    At the Effective Time, pursuant to the Merger Agreement, Rajeev Singh, Jeff Brodsky, Michael Hilton, Jeff Jordan, Cindy Kent, Peter Klein, Dawn Lepore, Elizabeth Nabel, and Pat Wadors, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.

    At the Effective Time, pursuant to the Merger Agreement, Rajeev Singh, Stephen Barnes, Rob Cavanaugh, and Richard Eskew, each of whom was an officer of the Company as of immediately prior to the Effective Time, ceased to be an officer of the Company. In connection with Mr. Cavanaugh’s and Mr. Eskew’s separation from the Company, each such officer and the Company entered into a separation agreement, pursuant to which each of Mr. Cavanaugh and Mr. Eskew will receive (i) a cash payment equal to 12 months of such officer’s base salary and (ii) up to 12 months of payment of COBRA group health insurance continuation. The foregoing description of such separation agreements does not purport to be complete and is subject to and qualified in its entirety by reference to the separation agreements, copies of which are filed as Exhibit 2.2 and Exhibit 2.3 hereto and are incorporated by reference herein.

    Item 5.03
    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    The information set forth in the Introductory Note and under Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.03.

    Effective upon completion of the Merger, the certificate of incorporation of the Company, as in effect immediately prior to the Merger, was amended and restated to be in the form of the certificate of incorporation attached as Exhibit 3.1 hereto. Such exhibit is incorporated by reference into this Item 5.03.

    Effective upon completion of the Merger, the bylaws of the Company, as in effect immediately prior to the Merger, were amended and restated to be in the form of the bylaws attached as Exhibit 3.2 hereto. Such exhibit is incorporated by reference into this Item 5.03.


    Item 9.01
    Financial Statements and Exhibits.

    (d)
    Exhibits

    Exhibit
    No.
    Exhibit Description
    2.1*
    Agreement and Plan of Merger, dated as of January 8, 2025, by and among Accolade, Inc., Transcarent, Inc. and Acorn Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on January 8, 2025).
    2.2
    Separation Agreement, dated as of March 29, 2025, by and between Accolade, Inc. and Robert Cavanaugh.
    2.3
    Separation Agreement, dated as of March 28, 2025, by and between Accolade, Inc. and Richard Eskew.
    3.1
    Amended and Restated Certificate of Incorporation of Accolade, Inc.
    3.2
    Amended and Restated Bylaws of Accolade, Inc.
    4.1
    First Supplemental Indenture, dated as of April 8, 2025, to the Indenture, dated March 29, 2021, by and between Accolade, Inc. and U.S. Bank Trust Company.
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document).

    * Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K.  The Company agrees to furnish supplementally to the SEC a copy of any omitted exhibits or schedules upon request. The Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules or exhibits so furnished.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

       
    ACCOLADE, INC.
         
     
    By:
    /s/ Rajeev Singh
       
    Rajeev Singh
       
    Chief Executive Officer
    Date: April 8, 2025
       



    Get the next $ACCD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACCD

    DatePrice TargetRatingAnalyst
    6/28/2024$13.00 → $8.00Buy
    Needham
    2/26/2024$16.00Outperform
    Leerink Partners
    1/17/2024$16.00 → $14.00Neutral
    DA Davidson
    1/3/2024$13.00Equal Weight
    Barclays
    5/24/2023$16.50Neutral → Buy
    BofA Securities
    4/12/2023$18.00Overweight
    Stephens
    3/23/2023$16.00Neutral → Buy
    Guggenheim
    2/9/2023$14.00Buy → Hold
    Jefferies
    More analyst ratings

    $ACCD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Singh Rajeev returned $10,429,525 worth of shares to the company (1,483,574 units at $7.03), closing all direct ownership in the company (SEC Form 4)

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:52:21 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form 4 filed by Director Lepore Dawn G

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:37:34 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Director Kent Cindy returned $84,093 worth of shares to the company (11,962 units at $7.03), closing all direct ownership in the company (SEC Form 4)

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:36:43 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Transcarent Completes Merger With Accolade

    Creating the Most Comprehensive Health and Care Platform for Employers and Health Plans Serving 20 Million Members & 1,700 Employer and Health Plan Clients Today Transcarent announced the successful completion of its merger with Accolade, the leading health advocacy, expert medical opinion, and virtual primary care company in the market. The combined organization now serves over 20 million Members and more than 1,700 employer and health plan clients as the One Place for Health and Care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407811112/en/ With the completion of the transaction, Transcarent will offer a health and car

    4/8/25 9:22:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Stockholders Approve Merger Between Accolade and Transcarent

    SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting of stockholders (the "Special Meeting") held earlier today. The final, certified voting results for the Special Meeting will be provided in a Form 8-K filed with the U.S. Securities and Exchange Commission. The transaction remains on track to be completed in the second quarter of calendar year 2025 and is subject to customary closing conditions, including the receipt of certain state regulatory approvals. Upon completion of the transaction, Accolade will become a privately held company and shares of Accol

    3/27/25 4:05:00 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Welcomes Oshi Health to Trusted Partner Ecosystem

    Partnership increases access to specialized, whole-person clinical care for people managing digestive health conditions SEATTLE, March 6, 2025 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD) has partnered with Oshi Health, a leading virtual clinic specializing in gastrointestinal (GI) conditions that delivers convenient, accessible, whole-person care through a collaborative, multidisciplinary approach. This partnership adds to Accolade's existing GI health partnership with Cylinder and reinforces Accolade's commitment to delivering best-in-class health solutions to customers and their employee and member populations.

    3/6/25 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Accolade with a new price target

    Needham reiterated coverage of Accolade with a rating of Buy and set a new price target of $8.00 from $13.00 previously

    6/28/24 7:50:50 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Leerink Partners initiated coverage on Accolade with a new price target

    Leerink Partners initiated coverage of Accolade with a rating of Outperform and set a new price target of $16.00

    2/26/24 7:00:19 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    DA Davidson resumed coverage on Accolade with a new price target

    DA Davidson resumed coverage of Accolade with a rating of Neutral and set a new price target of $14.00 from $16.00 previously

    1/17/24 7:07:47 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    SEC Filings

    View All

    SEC Form 15-12G filed by Accolade Inc.

    15-12G - Accolade, Inc. (0001481646) (Filer)

    4/18/25 9:10:20 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13D/A filed by Accolade Inc.

    SCHEDULE 13D/A - Accolade, Inc. (0001481646) (Subject)

    4/10/25 9:03:06 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form 25-NSE filed by Accolade Inc.

    25-NSE - Accolade, Inc. (0001481646) (Subject)

    4/8/25 3:43:21 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Leadership Updates

    Live Leadership Updates

    View All

    Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction

    SAN FRANCISCO and SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, today announced the expiration of the waiting period under the Hart-Scott-Rodino ("HSR") Antitrust Improvements Act of 1976 with respect to the previously announced merger between the two companies. The transaction remains on track to be completed in the second quarter of calendar year 2025, subject to Accolade stockholder approval and satisfaction of other customary closing conditions. Glen Tullman, Chief Executive Officer of Transcarent, said, "With this milestone behind us, we ar

    2/24/25 5:20:27 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Expands Physician-Executive Leadership to Enhance Care Delivery and Improve the Healthcare Experience

    Welcomes Dr. Connie Hwang as chief medical officer, creates roles of chief health officer and chief nursing officer SEATTLE, Sept. 18, 2023 /PRNewswire/ -- Accolade (NASDAQ:ACCD) announced the expansion of its care delivery team, strengthening the company's ability to streamline healthcare experiences through physician-led advocacy. Connie Hwang, MD, MPH, joins Accolade to lead population health strategies for employers and health plans. Led by Shantanu Nundy, MD, executive vice president, chief health officer, the care delivery leadership team includes Dr. Hwang, senior vice president, chief medical officer; James Wantuck, MD, senior vice president, associate chief medical officer and co-fo

    9/18/23 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade appoints new chief information security officer

    With the addition of senior vice president and CISO, Kelli Burns, Accolade further elevates its focus on trusted, personalized relationships through exceptional information security for its members and customers SEATTLE, July 25, 2022 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), the company that provides millions of people and their families with Personalized Healthcare, announced today that Kelli Burns has joined the organization as senior vice president, chief information security officer. Burns, a former consultant with Ernst & Young LLP (EY US) focused on cybersecurity en

    7/25/22 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Financials

    Live finance-specific insights

    View All

    Transcarent To Acquire Accolade

    Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment Transcarent's Generative AI WayFinding and care experiences combined with Accolade's Advocacy, Expert Medical Opinion, and Primary Care will deliver on the promise of ‘One Place for Health and Care' Accolade shareholders to receive $7.03 per share in cash SAN FRANCISCO and SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent wil

    1/8/25 8:30:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade to Announce Fiscal Third Quarter 2025 Financial Results

    SEATTLE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here. (https://register.vevent.com/register/BI0dce2f02ed2f44c8901127623aa788c3) Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via a li

    12/16/24 8:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Announces Results for Fiscal Second Quarter 2025

    SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. "As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamentally designed to improve the lives of millions of people and their families. Our focus remains on solving the Physician Gap through a physician-led advocacy approach that engages the entire healthcare ecosystem and enables a better healthcare experience for our members," s

    10/8/24 7:00:29 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    SC 13G/A - Accolade, Inc. (0001481646) (Subject)

    11/14/24 7:34:26 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    SC 13G/A - Accolade, Inc. (0001481646) (Subject)

    11/12/24 12:26:15 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form SC 13G filed by Accolade Inc.

    SC 13G - Accolade, Inc. (0001481646) (Subject)

    11/4/24 11:51:44 AM ET
    $ACCD
    Business Services
    Consumer Discretionary